Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System

Show full item record



Permalink

http://hdl.handle.net/10138/321632

Citation

Cerullo , V , Capasso , C , Vähä-Koskela , M , Hemminki , O & Hemminki , A 2018 , ' Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System ' , Current Cancer Drug Targets , vol. 18 , no. 2 , pp. 124-138 . https://doi.org/10.2174/1568009617666170502152352

Title: Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Author: Cerullo, Vincenzo; Capasso, Cristian; Vähä-Koskela, Markus; Hemminki, Otto; Hemminki, Akseli
Contributor: University of Helsinki, Faculty of Pharmacy
University of Helsinki, Division of Pharmaceutical Biosciences
University of Helsinki, Institute for Molecular Medicine Finland
University of Helsinki, Translational Cancer Biology (TCB) Research Programme
University of Helsinki, Clinicum
Date: 2018
Language: eng
Number of pages: 15
Belongs to series: Current Cancer Drug Targets
ISSN: 1568-0096
URI: http://hdl.handle.net/10138/321632
Abstract: Adenovirus is one of the most commonly used vectors for gene therapy and it is the first approved virus-derived drug for treatment of cancer. As an oncolytic agent, it can induce lysis of infected cells, but it can also engage the immune system, promoting activation and maturation of antigen-presenting cells (APCs). In essence, oncolysis combined with the associated immunostimulatory actions result in a "personalized in situ vaccine" for each patient. In order to take full advantage of these features, we should try to understand how adenovirus interacts with the immune system, what are the receptors involved in triggering subsequent signals and which kind of responses they elicit. Tackling these questions will give us further insight in how to manipulate adenovirus-mediated immune responses for enhancement of anti-tumor efficacy. In this review, we first highlight how oncolytic adenovirus interacts with the innate immune system and its receptors such as Toll-like receptors, nucleotide-binding and oligomerization domain (NOD)-like receptors and other immune sensors. Then we describe the effect of these interactions on the adaptive immune system and its cells, especially B and T lymphocytes. Finally, we summarize the most significant preclinical and clinical results in the field of gene therapy where researchers have engineered adenovirus to manipulate the host immune system by expressing cytokines and signal-ingmediators.
Subject: Oncolytic adenovirus
gene therapy
innate immune system
adaptive immune system
pattern recognition receptors
armed oncolytic adenovirus
toll-like receptors
PHASE-I TRIAL
BETA GENE-THERAPY
NOD-LIKE RECEPTORS
REPLICATION-SELECTIVE ADENOVIRUS
METASTATIC PLEURAL EFFUSIONS
HELPER-DEPENDENT ADENOVIRUS
REFRACTORY SOLID TUMORS
T-CELL-ACTIVATION
GM-CSF
INTRATUMORAL INJECTION
3111 Biomedicine
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Final_3_Cerullo_Adv_and_immunity_updated_2_.pdf 662.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record